Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

NCT03834961 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03834961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03834961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 25, 2019
Completion date
July 25, 2027
Enrollment
33 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system neoplasm, infantile fibrosarcoma, recurrent acute leukemia, refractory acute leukemia, solid neoplasm